IP Library Granted Patent US 8,097,435
Granted Patent B2
US 8,097,435 · App. 12/401,746 · Granted Jan 17, 2012

Polynucleotides encoding long-acting growth hormone polypeptides and methods of producing same

Assignee: Prolor Biotech Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,435
App. No.
12/401,746
Granted
Jan 17, 2012
Kind
B2
Abstract

A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a peptide-of-interest are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.

Claims (18)

1. A polynucleotide molecule consisting of a DNA sequence encoding a polypeptide, said polypeptide consisting of a hGH polypeptide, one chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said hGH polypeptide, and two chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said hGH polypeptide.

2. The polynucleotide of claim 1 , wherein said DNA sequence is selected from the group consisting of SEQ ID NO: 45 and SEQ ID NO: 46.

3. An expression vector comprising the polynucleotide of claim 1 .

4. An isolated cell comprising the expression vector of claim 3 .

5. A composition comprising the expression vector of claim 3 and a carrier.

6. A polynucleotide molecule consisting of a DNA sequence encoding a polypeptide, said polypeptide consisting of a hGH polypeptide, one chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said hGH polypeptide, two chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said hGH polypeptide, and a signal peptide attached to the amino terminus of said one chorionic gonadotrophin carboxy terminal peptide.

7. The polynucleotide of claim 6 , wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19.

8. An expression vector comprising the polynucleotide of claim 6 .

9. A method of producing a hGH polypeptide with an improved biological half life in an isolated cell, comprising the step of transfecting said cell with an expression vector of claim 3 or claim 8 , thereby producing a hGH polypeptide with an improved biological half life in an isolated cell.

10. An isolated cell comprising the expression vector of claim 8 .

11. A composition comprising the expression vector of claim 8 and a carrier.

12. A method of producing a hGH polypeptide having a biological activity in an isolated cell, comprising the step of transfecting said cell with an expression vector comprising a coding portion encoding a polypeptide, said polypeptide consisting of a hGH polypeptide, 2 chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said hGH polypeptide, and 1 chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said hGH polypeptide, thereby producing a hGH polypeptide having a biological activity in an isolated cell.

13. The method of claim 12 , wherein said coding portion is selected from the group consisting of SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46.

14. A method of producing a hGH polypeptide having a biological activity in an isolated cell, comprising the step of transfecting said cell with an expression vector comprising a coding portion encoding a polypeptide, said polypeptide consisting of a hGH polypeptide, 2 chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said hGH polypeptide, 1 chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said hGH polypeptide and a signal peptide attached:

(a) to the amino terminus of a chorionic gonadotrophin carboxy terminal peptide or

(b) to the amino terminus of said hGH polypeptide, thereby producing a hGH polypeptide having a biological activity in an isolated cell.

15. The method of claim 12 or claim 14 , wherein said biological activity is induction of weight gain.

16. The method of claim 14 , wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19.

Assignments (7)
SECURITY INTEREST Recorded Jul 17, 2024
From: OPKO BIOLOGICS LTD.
To: HCR INJECTION SPV, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 068407/0549 →
CHANGE OF NAME Recorded May 23, 2014
From: PROLOR BIOTECH LTD.
To: OPKO BIOLOGICS LTD.
Reel/Frame 033015/0859 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT RECEIVING PARTY DATA NAME: MODIGENE INC PREVIOUSLY RECORDED ON REEL 022596 FRAME 0237. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTED RECEIVING PARTY DATA NAME: MODIGENETECH LTD. Recorded Aug 12, 2013
From: FARES, FUAD; FIMA, UDI EYAL
To: MODIGENETECH LTD
Reel/Frame 031003/0343 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 026654 FRAME 0210. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ASSIGNEE ADDRESS IS GOLDA MEIR ST.7, 2ND FLOOR, NES ZIONA 74140, ISRAEL.. Recorded Oct 10, 2011
From: MODIGENETECH LTD.
To: PROLOR BIOTECH LTD.
Reel/Frame 027035/0432 →
CHANGE OF NAME Recorded Jul 27, 2011
From: MODIGENETECH LTD.
To: PROLOR BIOTECH LTD.
Reel/Frame 026654/0210 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED ON REEL 022596 FRAME 0237. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE'S CORRECT NAME IS MODIGENETECH LTD.. Recorded Apr 13, 2010
From: FARES, FUAD; FIMA, UDI EYAL
To: MODIGENETECH LTD.
Reel/Frame 024221/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2009
From: FARES, FUAD; FIMA, UDI EYAL
To: MODIGENE INC
Reel/Frame 022596/0237 →
Continuity (3)
Continuation 11700910 · Feb 1, 2007
Provisional Application 60764761 · Feb 3, 2006
Related Publication 20090270489A1 · Oct 29, 2009